BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 11125287)

  • 1. [Immunotargeting of tumors: state of the art and prospects in 2000].
    Pèlegrin A; Xavier F; Barbet J; Bartholeyns J; Baty D; Buchegger F; Chatal JF; Dufief F; Gurreau D; Gruaz-Guyon A; Lamotte D; Leserman L; Mach JP; Robert B; Saccavini JC; Teillaud JL; Teulon I
    Bull Cancer; 2000 Nov; 87(11):777-91. PubMed ID: 11125287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Radioimmunotargeting: diagnosis and therapeutic use].
    Vuillez JP
    Bull Cancer; 2000 Nov; 87(11):813-27. PubMed ID: 11125290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma.
    Sharkey RM; Karacay H; Johnson CR; Litwin S; Rossi EA; McBride WJ; Chang CH; Goldenberg DM
    J Nucl Med; 2009 Mar; 50(3):444-53. PubMed ID: 19223402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radioimmunotherapy of human colon cancer xenografts using a dimeric single-chain Fv antibody construct.
    Pavlinkova G; Booth BJ; Batra SK; Colcher D
    Clin Cancer Res; 1999 Sep; 5(9):2613-9. PubMed ID: 10499640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing bispecific antibody pretargeting for use in radioimmunotherapy.
    Sharkey RM; Karacay H; Richel H; McBride WJ; Rossi EA; Chang K; Yeldell D; Griffiths GL; Hansen HJ; Goldenberg DM
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3897S-913S. PubMed ID: 14506188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
    Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Use of antibodies or their fragments for the treatment of tumors].
    Douillard JY; Chatal JF
    Bull Cancer; 1998 Nov; 85(11):951-9. PubMed ID: 9951422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved therapy of non-Hodgkin's lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibody.
    Sharkey RM; Karacay H; Chang CH; McBride WJ; Horak ID; Goldenberg DM
    Leukemia; 2005 Jun; 19(6):1064-9. PubMed ID: 15815716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-guided radiation therapy of cancer.
    Koppe MJ; Postema EJ; Aarts F; Oyen WJ; Bleichrodt RP; Boerman OC
    Cancer Metastasis Rev; 2005 Dec; 24(4):539-67. PubMed ID: 16408161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
    Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted therapy of athymic mice bearing GW-39 human colonic cancer micrometastases with 131I-labeled monoclonal antibodies.
    Blumenthal RD; Sharkey RM; Haywood L; Natale AM; Wong GY; Siegel JA; Kennel SJ; Goldenberg DM
    Cancer Res; 1992 Nov; 52(21):6036-44. PubMed ID: 1394228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radioimmunoconjugates for the treatment of cancer.
    Kraeber-Bodéré F; Bodet-Milin C; Rousseau C; Eugène T; Pallardy A; Frampas E; Carlier T; Ferrer L; Gaschet J; Davodeau F; Gestin JF; Faivre-Chauvet A; Barbet J; Chérel M
    Semin Oncol; 2014 Oct; 41(5):613-22. PubMed ID: 25440606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The promise of immuno-PET in radioimmunotherapy.
    Verel I; Visser GW; van Dongen GA
    J Nucl Med; 2005 Jan; 46 Suppl 1():164S-71S. PubMed ID: 15653665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis of and therapy for solid tumors with radiolabeled antibodies and immune fragments.
    Carrasquillo JA; Krohn KA; Beaumier P; McGuffin RW; Brown JP; Hellström KE; Hellström I; Larson SM
    Cancer Treat Rep; 1984 Jan; 68(1):317-28. PubMed ID: 6607111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radioimmunotherapy of non-Hodgkin's lymphoma: molecular targeting and novel agents.
    Pauwels EK; Erba P
    Drug News Perspect; 2007 Mar; 20(2):87-93. PubMed ID: 17440631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Status of radioimmunotherapy in the new millennium.
    Imam SK
    Cancer Biother Radiopharm; 2001 Jun; 16(3):237-56. PubMed ID: 11471488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioimmunoimaging and radioimmunotherapy: will these be routine procedures?
    Bischof Delaloye A
    Semin Nucl Med; 2000 Jul; 30(3):186-94. PubMed ID: 10928382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor effects of ricin A chain immunotoxins prepared from intact antibodies and Fab' fragments on solid human Hodgkin's disease tumors in mice.
    Engert A; Martin G; Pfreundschuh M; Amlot P; Hsu SM; Diehl V; Thorpe P
    Cancer Res; 1990 May; 50(10):2929-35. PubMed ID: 1692251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current status of therapy of solid tumors.
    Jhanwar YS; Divgi C
    J Nucl Med; 2005 Jan; 46 Suppl 1():141S-50S. PubMed ID: 15653662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immunoscintigraphy and radioimmunotherapy of cancer using monoclonal antibodies].
    Oriuchi N
    Gan To Kagaku Ryoho; 1999 May; 26(6):762-7. PubMed ID: 10410144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.